Kirsten ratsarcoma viral oncogene homolog (KRAS) mutation represents the most prevalent mutational subtype in human cancers; oncogenic KRAS mutations—particularly those affecting codons G12 and G13—impair GTPase activity, thereby driving constitutive pathway activation and aberrant signal transduction in cancer cells [2]. Here, KRAS is linked to cancer.